Maternal and Infant Bone Mineral Density 1 Year After Delivery in a Randomized, Controlled Trial of Maternal Tenofovir Disoproxil Fumarate to Prevent Mother-to-child Transmission of Hepatitis B Virus

Nicolas Salvadori; Bo Fan; Waralee Teeyasoontranon; Nicole Ngo‐Giang‐Huong; Siriluk Phanomcheong; Anita Luvira; Achara Puangsombat; Arunrat Suwannarat; Ussanee Srirompotong; Chaiwat Putiyanun; Tim R. Cressey; Luc Decker; Woottichai Khamduang; Linda J. Harrison; Camlin Tierney; John Shepherd; Athena P. Kourtis; Marc Bulterys; George K. Siberry; Gonzague Jourdain

doi:10.1093/cid/ciy982

Ask about this paper

Answers are grounded in this paper and cite their sources.

Abstract

In a randomized, double-blind, placebo-controlled trial of tenofovir disoproxil fumarate (TDF) use from 28 weeks gestational age to 2 months postpartum to prevent mother-to-child transmission of hepatitis B virus, there was no significant effect of maternal TDF use on maternal or infant bone mineral density 1 year after delivery/birth. Clinical Trials Registration. NCT01745822.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Salvadori et al. (2019) studied this question.

synapsesocial.com/papers/6ab1d00f9d5882a56a73d94b https://doi.org/10.1093/cid/ciy982

View Full Paper

Ask AI

Bookmark

Share

Maternal and Infant Bone Mineral Density 1 Year After Delivery in a Randomized, Controlled Trial of Maternal Tenofovir Disoproxil Fumarate to Prevent Mother-to-child Transmission of Hepatitis B Virus

Ask about this paper

Abstract

Discussion

Cite This Study

Maternal and Infant Bone Mineral Density 1 Year After Delivery in a Randomized, Controlled Trial of Maternal Tenofovir Disoproxil Fumarate to Prevent Mother-to-child Transmission of Hepatitis B Virus

Ask about this paper

Abstract

Discussion

Cite This Study

Keep reading

Keep reading